1. A heavy-chain immunoglobulin single variable domain (ISVD), in which the amino acid residue at position 89 is L and the amino acid residue at position 11 is V, wherein the amino acid residues/positions are indicated with the numbering according to Kabat.

2. The heavy-chain ISVD according to claim 1 that contains an amino acid at position 110 that is chosen from T, I, A, K or Q; (ii) contains an amino acid at position 112 that is chosen from S, F, K or Q; and (iii) optionally contains a P14A or A14P substitution and/or a Q108L substitution.

3. The heavy-chain ISVD according to claim 2 that contains an amino acid at position 110 that is chosen from T, K or Q; (ii) contains an amino acid at position 112 that is chosen from S, K or Q; and (iii) optionally contains a P14A or A14P substitution and/or a Q108L substitution.

4. The heavy-chain ISVD according to claim 3 that contains an amino acid at position 110 that is T; (ii) contains an amino acid at position 112 that is chosen from S; and (iii) optionally contains a P14A or A14P substitution and/or a Q108L substitution.

5. The heavy-chain ISVD according to any one of claims 1 to 4, in which said VH domain contains a C-terminal extension $(X)_n$, in which n is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2, such as 1); and each X is an (preferably naturally occurring) amino acid residue that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I).

6. The heavy-chain ISVD according to claim 4 or claim 5, respectively, in which the C-terminal end is the C-terminal end is either VTVSS (SEQ ID NO: 76) or VTVSS$(X)_n$ (SEQ ID NO: 77), respectively, in which X and n are as defined in claim 5.

7. The heavy-chain ISVD according to claim 6, which is a nanobody.

8. The heavy-chain ISVD according to claim 1, in which the C-terminal end of the VH domain is one of: VTVSS (SEQ ID NO:76), VTVSS(X)n (SEQ ID NO:77), VTVKS (SEQ ID NO:1), VTVKS(X)n (SEQ ID NO:21), VTVQS (SEQ ID NO:2), VTVQS(X)n (SEQ ID

NO:22), VKVSS (SEQ ID NO: 95), VKVSS(X)n (SEQ ID NO:97), VQVSS (SEQ ID NO: 96), VQVSS(X)n (SEQ ID NO: 98), VZVZS (SEQ ID NO: 107, in which each amino acid residue Z is independently K or Q) or VZVZSX(n) (SEQ ID NO:108, in which each amino acid residue Z is independently K or Q), in which n is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2, such as 1); and each X is an (preferably naturally occurring) amino acid residue that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I).

9. Heavy-chain ISVD according to claim 8, in which the C-terminal end of the VH domain is one of VTVSS (SEQ ID NO:76), VKVSS (SEQ ID NO: 95), VQVSS (SEQ ID NO: 96), VKVSS(X)n (SEQ ID NO:97) or VQVSS(X)n (SEQ ID NO: 98), in which X and n are as defined in claim 8.

10. Heavy-chain ISVD according to claim 8 or claim 9, in which the C-terminal end of the VH domain is one of VTVSS (SEQ ID NO:76) or VTVSS(X)n (SEQ ID NO:77), in which X and n are as defined in claim 8.

11. Heavy-chain ISVD according to any one of claims 8 to 10, which is an immunoglobulin single variable domain.

12. Heavy-chain ISVD according to claim 11, which is a nanobody.

13. Heavy-chain ISVD, in which:

- the amino acid residue at position 11 is V; and
- the amino acid residue at position 14 is one of A or P; and
- the amino acid residue at position 41 is one of A or P; and
- the amino acid residue at position 89 is L; and
- the amino acid residue at position 108 is one of Q or L; and
- the amino acid residue at position 110 is one of T, K or Q; and
- the amino acid residue at position 112 is one of S, K or Q;

and in which said VH domain optionally contains a C-terminal extension (X)n , in which n is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2, such as 1); and each X is an (preferably naturally occurring) amino acid residue that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I),

wherein the amino acid residues/positions are indicated with the numbering according to Kabat.

14. Heavy-chain ISVD according to claim 13, which is a nanobody.

15. Heavy-chain ISVD according to any one of the preceding claims, which is directed to serum albumin.

16. Heavy-chain ISVD according to claim 15, in which:
- CDR1 is the amino acid sequence SFGMS (SEQ ID NO:41);
- CDR2 is the amino acid sequence SISGSGSDTLYADSVKG (SEQ ID NO:42);
- CDR3 is the amino acid sequence GGSLSR (SEQ ID NO:43).

17. Heavy-chain ISVD according to claim 16, which has at least 95% sequence identity with at least one of Alb-1 (SEQ ID NO: 52 of WO 2006/122787 as defined in Figure 32), Alb-8 (SEQ ID NO: 46) and/or Alb-23 (SEQ ID NO:61).

18. Library of heavy-chain ISVDs according to any one of claims 1 to 17.

19. Library of nucleic acid residues encoding heavy-chain ISVDs according to any of claims 1 to 17.

20. Library according to claim 19, which is an expression library.

21. Library according to any one of claims 18 to 20, which is a synthetic library.

22. Library according to any one of claims 18 to 21, which contains at least 100 different sequences, such as at least 1000 different sequences, in particular more than 10^5 different sequences, more in particular more than 10^6 different sequences, such as 10^8 to 10^{10} or more different sequences.

23. Polypeptide, construct or compound that comprises at least one heavy-chain immunoglobulin single variable domain according to any one of claims 1 to 17.

24. Nucleic acid that encodes the heavy-chain immunoglobulin single variable domain according to any one of claims 1 to 17 or the polypeptide, construct or compound according to claim 23.

25. A method for producing the heavy-chain immunoglobulin single variable domain according to any one of claims 1 to 17 or the polypeptide, construct or compound according to claim 23, optionally comprising expressing the nucleic acid according to claim 24 in a suitable host organism.

26. A composition comprising the heavy-chain immunoglobulin single variable domain according to any one of claims 1 to 17, the polypeptide, construct or compound according to claim 23 or the nucleic acid according to claim 24, wherein the composition is optionally a pharmaceutical composition.

27. The heavy-chain immunoglobulin single variable domain according to any one of claims 1 to 17 or the polypeptide, construct or compound according to claim 23 for use in medicine.